Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ectodysplasin (Eda)-containing medicine for treating ocular surface diseases and corneal diseases

A technology for exogenous proteins and corneal diseases, which is applied in the field of drugs for the treatment of ocular surface and corneal diseases, can solve problems that have not been reported, and achieve the effect of promoting repair

Inactive Publication Date: 2014-08-06
XIAMEN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application of this Eda protein to the treatment of ocular surface and corneal related diseases has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ectodysplasin (Eda)-containing medicine for treating ocular surface diseases and corneal diseases
  • Ectodysplasin (Eda)-containing medicine for treating ocular surface diseases and corneal diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Take 4 C57 mice of the same age, remove the central corneal epithelium, remove the eyeballs, put the eyeballs into 1% FBS for culture, and randomly divide them into Eda administration group and control group, add 10ng The Eda protein of / ml is administered once in 12h, and is administered continuously for 36h, and at 0h, 12h, 24h, and 36h, the cornea is stained with sodium fluorescein, measures its damage and repair area, and calculates the corneal epithelial repair rate (specifically Such as figure 1 shown). It can be concluded that Eda protein can promote the repair of corneal epithelium.

Embodiment 2

[0022] Select 6 wild-type (WT) mice and 6 Eda gene mutant (Ta) mice 5 weeks after birth, and give 7ul of Eda eye drops with a concentration of 10ng / ml to the right eye of the mice each time, once every 6 hours , administered continuously for three weeks, the same dose of Eda eye drops solvent PBS was administered to its left eye. three weeks later, if figure 2 As shown, compared with the Ta-PBS group, the fluorescein sodium staining of the cornea in the Ta-Eda group was significantly reduced, and the ocular surface lesions were improved; in both the WT-Eda group and the WT-PBS group, no corneal abnormalities were seen. It can be concluded that the Eda protein has no toxicity to the cornea, and has the effect of treating ocular surface diseases in Eda gene mutant mice.

Embodiment 3

[0024] The preparation method of eye drop, comprises the steps:

[0025] 1. Precisely weigh 0.001-1000mg of natural Eda protein or Eda recombinant protein, 0.1-50g of pH regulator, 0.1-50g of isotonic agent, and 0.01-5g of stabilizer;

[0026] 2. First fully dissolve the natural Eda protein or Eda recombinant protein with 1-50 times the amount of dissolving agent, stir and mix, adjust the pH range: 7.0-8.0, and dilute to 1000ml with water for injection to obtain the medicinal solution;

[0027] 3. In a class 100 environment, the liquid medicine obtained in step 1 can be filtered through a microporous membrane for 1 to 5 times;

[0028] 4. In a class 100 environment, fill the liquid medicine into a single-dose packaging container, seal it, and obtain the finished product.

[0029] The dissolving agent is propylene glycol and / or hydroxypropyl beta cyclodextrin; the pH regulator is sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an ectodysplasin (Eda)-containing medicine for treating ocular surface diseases and corneal diseases. An effective component of the ectodysplasin-containing medicine is ectodysplasin with the concentration of 1ng / mL-1mg / mL, and the ectodysplasin is natural ectodysplasin and / or recombinant ectodysplasin. The ectodysplasin (Eda)-containing medicine has the advantages that the ectodysplasin is used as the effective component, and therefore, the ectodysplasin-containing medicine has no toxicity on corneas and has the effects of promoting corneal epithelium restoration and treating the ocular surface diseases caused by Eda gene mutation.

Description

technical field [0001] The invention belongs to the field of treating ocular surface and corneal diseases, and in particular relates to a medicine for treating ocular surface and corneal diseases. Background technique [0002] Ectodysplasin, the Chinese name is foreign foreign protein, referred to as Eda. It is a conserved protein. In different species, Eda protein has almost the same amino acid sequence and similar structure. Congenital deficiency of Eda protein can cause hypohidrotic ectodermal dysplasia syndrome (XLHED). The disease is a relatively common genetic disease syndrome, and patients will have clinical manifestations such as dry eye, keratitis and conjunctivitis. However, there is no report on the application of the Eda protein in the treatment of ocular surface and corneal related diseases. Contents of the invention [0003] The object of the present invention is to provide a medicine for the treatment of ocular surface and corneal diseases, which contains...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P27/02
Inventor 李炜李三明张丽颖李娟刘祖国
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com